Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma (Q64064520)

9

Paolo A Ascierto

0 references

Christian U Blank

10

Christian U Blank

0 references

Reinhard Dummer

17

Reinhard Dummer

0 references

Dirk Schadendorf

6

Dirk Schadendorf

0 references

author name string

Carla M L van Herpen

1

0 references

Sanjiv S Agarwala

2

0 references

Axel Hauschild

3

0 references

Carola Berking

4

0 references

J Thaddeus Beck

5

0 references

Rob Jansen

7

0 references

Paola Queirolo

8

0 references

Michael C Heinrich

11

0 references

Rupam R Pal

12

0 references

Adnan Derti

13

0 references

Victor Antona

14

0 references

Heidi Nauwelaerts

15

0 references

Angela Zubel

BRAF mutation predicts sensitivity to MEK inhibition

16

0 references

language of work or name

English

0 references

publication date

5 March 2019

0 references

published in

Oncotarget

0 references

volume

10

0 references

issue

19

0 references

page(s)

1850-1859

0 references

cites work

1 reference

12 December 2020

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

1 reference

12 December 2020

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

1 reference

12 December 2020

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

1 reference

12 December 2020

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

1 reference

12 December 2020

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

1 reference

12 December 2020

Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype

1 reference

12 December 2020

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

12 December 2020

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma

1 reference

12 December 2020

Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells

1 reference

12 December 2020

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

1 reference

12 December 2020

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

1 reference

12 December 2020

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

12 December 2020

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

12 December 2020

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

1 reference

12 December 2020

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

12 December 2020

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

12 December 2020

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

12 December 2020

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.

1 reference

12 December 2020

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma

1 reference

12 December 2020

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

1 reference

12 December 2020

Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies

1 reference

12 December 2020